Law360: AstraZeneca Gets Seroquel Pay-For-Delay Case Cut In Half

July 07, 2022

US District Judge Colm F. Connolly ruled that an estimated US$107 million tradeoff between AstraZeneca and Accord Healthcare does not prove that the two agreed to a “pay-for-delay” deal. The decision is part of a 2019 suit brought by a putative class alleging that AstraZeneca engaged in “pay-for-delay” agreements with Par Pharmaceuticals, Handa, and Accord. Par is represented by Stephen J. McIntyre, Brett J. Williamson, and Ben Bradshaw of O’Melveny & Myers LLP.

Read the full article here.

{{item.primary.intro}} {{item.primary.title}}

{{item.primary.search_title}}

{{item.primary.intro}} {{item.primary.title}}

{{item.primary.intro}} {{item.primary.title}}

{{item.primary.intro}} {{item.primary.title}}

{{item.primary.intro}} {{item.primary.title}}

{{item.primary.big_topic_title}}

{{item.primary.search_title}}

in the news